Objects
Gray, O. M., Jolley, D., Lechner-Scott, J., Zwanikken, C., Trojano, M., Grand'Maison, F., Duquette, P., Grammond, P., Bergamaschi, R., Giuliani, G., Taffi, R.. Association of South East Asian Nations, Neurological Association; 2008. The Multiple Sclerosis Severity Score (MSSS) re-examined: EDSS rank stability in the MSBase dataset increases five years after onset of multiple sclerosis.
Malhotra, S., Morcillo-Suárez, C., Chan, A., Vandenbroeck, K., Navarro, A., Bustamante, M. F., Rio, J., Akkad, D. A., Giacalone, G., Sánchez, A. J., Leyva, L., Alvarez-Lafuente, R., Brassat, D., Zettl, U. K., Oksenberg, J., Montalban, X., Comabella, M., Goertsches, R., Lechner-Scott, J., Urcelay, E., Fernández, O., Drulovic, J., García-Merino, A., Boneschi, F. Martinelli. Elsevier; 2011. IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis.
Lorscheider, J., Kuhle, J., Grand'Maison, F., Grammond, P., Sola, P., Ferraro, D., Trojano, M., Ramo-Tello, C., Lechner-Scott, J., Pucci, E., Solaro, C., Slee, M., Izquierdo, G., Van Pesch, V., Sanchez Menoyo, J. L., van der Walt, A., Butzkueven, H., Kappos, L., Kalincik, T., Lugaresi, A., Havrdova, E., Horakova, D., Hupperts, R., Duquette, P., Girard, M., Prat, A.. Wiley-Blackwell Publishing; 2019. Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.
O'Gorman, C., Freeman, S., Kilpatrick, T. J., Lechner-Scott, J., Moscato, P., Perreau, V. M., Scott, R. J., Stankovich, J., Stewart, G. J., Chapman, C., Marriot, M., Tanner, M., Taylor, B. V., Tubridy, N., Wiley, J., Butzkueven, H., Broadley, S. A., Bahlo, M., Booth, D. R., Brown, M. A., Foote, S. J., Griffiths, L. R.. BMJ Group; 2011. Familial recurrence risks for multiple sclerosis in Australia.
Bergamaschi, R., Montomoli, C., Boz, C., Iuliano, G., Zwanikken, C., Petersen, T., Lechner-Scott, J., Hupperts, R., Butzkueven, H., Pucci, E., Oreja-Guevara, C., Cristiano, E., Mallucci, G., Pia Amato, M. P., Havrdova, E., Fernandez-Bolanos, R., Spelman, T., Trojano, M., Lugaresi, A., Izquierdo, G., Grand'Maison, F., Duquette, P., Shaygannejad, V., Alroughani, R., Grammond, P.. Wiley-Blackwell; 2015. BREMSO: a simple score to predict early the natural course of multiple sclerosis.
Verheul, F., Smolders, J., Comi, G., Izquierdo, G., Grammond, P., Lus, G., Petersen, T., Bergamaschi, R., Giuliani, G., Boz, C., Coniglio, G., Van Pesch, V., Trojano, M., Lechner-Scott, J., Cavalla, P., Granella, F., Avolio, C., Fiol, M., Poehlau, D., Saladino, M. L., Gallo, P., Deri, N., Oleschko Arruda, W., Lepore, V., Paine, M., Ferro, M., Barnett, M., Cabrera-Gomez, J. A., Slee, M., Moore, F., Shaw, C., Petkovska-Boskova, T., Rutherford, M., Engelsen, O., Zwanikken, C., Damoiseaux, J., Hupperts, R., Amato, M. P., Grand'Maison, F., Butzkueven, H., Marrosu, M., Duquette, P.. Wiley-Blackwell Publishing; 2013. Fluctuations of MS births and UV-light exposure.
Spelman, T., Mekhael, L., Grammond, P., Barnett, M., Lechner-Scott, J., Alroughani, R., Trojano, M., Lugaresi, A., Granella, F., Pucci, E., Vucic, S., Burke, T., Butzkueven, H., Hodgkinson, S., Havrdova, E., Horakova, D., Duquette, P., Izquierdo, G., Grand'Maison, F.. Wiley-Blackwell Publishing; 2016. Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
Ban, M., McCauley, J. L., Dudbridge, F., Wason, J., Robertson, N. P., De Jager, P. L., Hafler, D. A., Barcellos, L. F., Ivinson, A. J., Sexton, D., Oksenberg, J. R., Hauser, S. L., Zuvich, R., Pericak-Vance, M. A., Haines, J., Compston, A., Sawcer, S., Baker, A., Bergamaschi, L., Cox, M., Kemppinen, A., D'Alfonso, S., Guerini, F. R., Lechner-Scott, J.. Nature Publishing Group; 2010. A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis.
Simpson, S., Tan, H., Williams, D., van der Mei, I., Ausimmune/AusLong Investigators Group,, Otahal, P., Taylor, B., Ponsonby, A.-L., Lucas, R. M., Blizzard, L., Valery, P. C., Lechner-Scott, J., Shaw, C.. Wiley-Blackwell Publishing; 2016. Anxiety, depression and fatigue at 5-year review following CNS demyelination.
Mahurkar, S., Moldovan, M., Jokubaitis, V. G., McKay, F. C., Gatt, P. N., Fabis-Pedrini, M. J., Martinelli, V., Comi, G., Lechner-Scott, J., Kermode, A. G., Slee, M., Taylor, B. V., Suppiah, V., , , , , Sorosina, M., Clarelli, F., Liberatore, G., Malhotra, S., Montalban, X., Antigüedad, A., Krupa, M.. Nature Publishing Group; 2017. Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.
Lechner-Scott, J., Spencer, B., Girard, M., Grammond, P., Oreja-Guevara, C., Hupperts, R., Bergamaschi, R., Boz, C., Giuliani, G., Van Pesch, V., Iuliano, G., Fiol, M., De Malmanche, T., , , , , , , , , , , Attia, J.R., , , , , Fitzgerald, M., Trojano, M., Grand'Maison, F., Antonio C Gomez, J., Izquierdo, G., Duquette, P.. Sage; 2012. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude.
The International Multiple Sclerosis Genetics Consortium, Esposito, F., Patsopoulos, N. A., Lechner-Scott, J., Goris, A., Dobosi, R., Dubois, B., Rioux, J. D., Oturai, A. B., Sondergaard, H. B., Sellebjerg, F., Sorensen, P. S., Reunanen, M., Cepok, S., Koivisto, K., Cournu-Rebeix, I., Fontaine, B., Winkelmann, J., Gieger, C., Infante-Duarte, C., Zipp, F., Bergamaschi, L., Leone, M., Bergamaschi, R., Kockum, I., Cavalla, P., Lorentzen, A. R., Mero, I. L., Celius, E. G., Harbo, H. F., Spurkland, A., Comabella, M., Brynedal, B., Alfredsson, L., Bernardinelli, L., Leppa, V., Robertson, N. P., Hawkins, C. P., Barcellos, L. F., Beecham, G., Bush, W., Cree, B. A. C., Daly, M. J., Ivinson, A. J., Aubin, C., Compston, A., Booth, D. R., D'Alfonso, S., Haines, J. L., Hauser, S. L., Hemmer, B., Hillert, J., McCauley, J. L., Oksenberg, J., Olsson, T., Palotie, A., Peltonen, L., Heard, R. N., Pericak-Vance, M. A., Saarela, J., Sawcer, S. J., Stranger, B., Boneschi, F. M., Comi, G., Hafler, D. A., de Bakker, P. I. W., De Jager, P. L., Stewart, G. J., Cox, M., Scott, R. J.. Nature Publishing Group; 2010. IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
Lefort, M., Sharmin, S., Maillart, E., Zephir, H., Labauge, P., Defer, G., Lebrun-Frenay, C., Moreau, T., Berger, E., Clavelou, P., Pelletier, J., Stankoff, B., Andersen, J. B., Gout, O., Lechner-Scott, J., .,, .,, .,, .,, .,, .,, .,, .,, Vukusic, S., .,, .,, .,, .,, .,, .,, .,, .,, .,, .,, Casey, R., .,, .,, .,, .,, .,, .,, .,, .,, .,, .,, Debouverie, M., .,, .,, .,, .,, .,, .,, .,, .,, .,, .,, Edan, G., .,, .,, .,, .,, .,, .,, .,, .,, .,, .,, Ciron, J., .,, .,, .,, .,, .,, .,, .,, .,, .,, .,, Ruet, A., .,, .,, .,, .,, .,, .,, .,, .,, De Sèze, J.. BioMed Central; 2022. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.